DOSAGE FORMS OF SILDENAFIL IN THE MANAGEMENT OF ERECTILE DYSFUNCTION


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The experience in the management of erectile dysfunction shows that taking even the most effective medications in tablet form may be inconvenient due to the need for natural settings for intimacy. The phosphodiesterase type 5 inhibitor sildenafil, presented in the orally disintegrating film formulation (Dynamic Forward), differs from all forms of the drug for the treatment of erectile dysfunction available in the Russian pharmaceutical market. The drug in the form of a film makes it possible to realize a pathogenetic approach to treating ED without changing the patient’s habitual way of life.

Texto integral

Acesso é fechado

Sobre autores

V. Grigoryan

M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Email: doctor-grigoryan@mail.ru
Dr.Med.Sci., Prof. at the Department of Urology Moscow, Russia

M. Gazimiev

M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Email: gazimiev@yandex.ru
Dr.Med.Sci., Professor at the Department of Urology Moscow, Russia

Yu. Demidko

M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Email: demidko1@mail.ru
Dr.Med.Sci., Urologist at the Clinic of Urology Moscow, Russia

A. Baiduvaliev

M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Email: ashan72_b@mail.ru
Doctoral Student at the Department of Urology Moscow, Russia

Bibliografia

  1. Prins J., Blanker M.H., Bohnen A.M., Thomas S., Bosch J.L. Prevalence of erectile dysfunction: a systematic review of population-based studies. Int J Impot Res.2002;14(6):422-432.
  2. Schwarz E.R. Erectile dysunction. s.l. Oxford university press, 2013.
  3. Ghofrani H.A., Osterloh I.H., Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006;5(8):689-702.
  4. Francis S.H., Corbin J.D. Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. Expert Opin Drug Metab Toxicol. 2005;1(2):283-293. Review.
  5. Murthy K.S. Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle. Biochem J. 2001;360(Pt 1):199-208.
  6. Krotovskii G.S., Zudin A.M. Viagra - five years of success. M., 2003. 191 p.
  7. Vanin A.F. Nitric oxide - a regulator of cell metabolism. Sorosovskii obrazovatel’nyi zhurnal. 2011,7(11).
  8. Giuliano F., Hultling C., El Masry W.S., Smith M.D., Osterloh I.H., Orr M., Maytom M. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Sildenafil Study Group. Ann Neurol. 1999;46(1):15-21.
  9. Goldstein I., Stecher V., Carlsson M. Treatment response to sildenafil in men with erectile dysfunction relative to concomitant comorbidities and age. Int J Clin Pract. 2017;71(3-4).
  10. Padma-Nathan H., Steers W.D., Wicker P.A. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a doubleblind, placebo-controlled study of 329 patients. Sildenafil Study Group. Int J Clin Pract. 1998;52(6):375-379.
  11. Rendell M.S., Rajfer J., Wicker P.A., Smith M.D. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA. 1999;281(5):421-426.
  12. Instructions for the use of the drug Dynamico Forward. Russian (Инструкция по применению препарата ДИНАМИКО ФОРВАРД).
  13. Mustafin R.I., Garipova V.R., Selmin F., Tsiluzro F. Orally disintegrating drug dosage forms (a review). Razrabotka i registratsiya lekarstvennykh sredstv. 2015;4(13):34-38.
  14. Levitra ODT: on everyone’s tongue. Effektivnaya farmakoterapiya. 2012;5:54-60.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bionika Media, 2018